NR2F1 and melanoma: Combining BRAFi + MEKi with mTOR inhibitors (e.g., rapamycin) suppressed NR2F1-driven MRD and delayed relapse, suggesting that targeting NR2F1 or downstream pathways in DTP cells is a potentially viable strategy to overcome dormancy-like resistance to melanoma therapy.